Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Johnson and Johnson
QuintilesIMS
Healthtrust
Cipla
Farmers Insurance

Generated: July 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,241,918

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,241,918 protect, and when does it expire?

Patent 9,241,918 protects LUMIGAN and is included in one NDA.

This patent has thirty-four patent family members in twenty-two countries.

Summary for Patent: 9,241,918
Title:Enhanced bimatoprost ophthalmic solution
Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/254,543
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,241,918
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,241,918
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,241,918

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,241,918

PCT Information
PCT FiledMarch 04, 2010PCT Application Number:PCT/US2010/026151
PCT Publication Date:September 10, 2010PCT Publication Number: WO2010/102078

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
Fish and Richardson
McKesson
Covington
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.